Akums Drugs & Pharmaceuticals Ltd. has been granted a patent for its innovative “Dual Release Gastro-Resistant Composition”. The patent covers a novel tablet designed to treat gastroesophageal reflux disease (GERD). The invention is protected for 20 years from November 19, 2022. This patent strengthens Akums’ commitment to developing patient-friendly therapies.
Patent Approval for GERD Treatment
Akums Drugs has secured a patent for its “Dual Release Gastro-Resistant Composition,” effective for 20 years beginning November 19, 2022. This patented invention aims to improve the treatment of gastroesophageal reflux disease (GERD).
Innovative Dual-Release Tablet
The patented product is a Dual Release Proton Pump Inhibitor (PPI) tablet, a next-generation therapy for GERD. GERD affects approximately 14% of the global population, including an estimated 784 million people. In India, prevalence is around 15.6%.
This dual-release tablet is designed to release medicine in two phases: 50% in the duodenum and 50% in the ileum. This leads to extended drug absorption and duration, offering relief from heartburn and improving patient compliance.
Technology and Benefits
The tablet uses tablet-in-tablet technology, enhancing stability and drug release. This once-daily formulation is DCGI approved and reflects Akums’ dedication to innovative therapies for acid-related disorders.
Source: BSE
